期刊文献+

玻璃体腔内药物缓释系统防治增生性玻璃体视网膜病变的研究进展 被引量:1

原文传递
导出
摘要 增生性玻璃体视网膜病变(PVR)是裂孔性和外伤性视网膜脱离及视网膜手术复位后的严重并发症,也是造成手术失败和患者视力丧失的主要原因。各种抗增生药物是辅助玻璃体手术治疗PVR的有效途径,缓释系统的应用不但使药物在玻璃体腔内能以有效浓度缓慢持续发挥效应,而且实现了多种抗增生药物的联合应用,针对性地作用于PVR不同病理过程,大大提高了药物疗效,同时,也减少了抗增生药对眼内组织的毒副作用。
出处 《国际眼科纵览》 2006年第3期159-162,共4页 International Review of Ophthalmology
  • 相关文献

参考文献6

  • 1张皙,张喜梅,蔡文泉,李佩娟.地塞米松缓释微粒在增生性玻璃体视网膜病变的应用[J].临床眼科杂志,2003,11(1):3-5. 被引量:3
  • 2刘瑜玲,陈改清,张强,徐亮,张士元,何蕾.玻璃体内持续释放肝素防治牵引性视网膜脱离的实验研究[J].眼科研究,2000,18(4):305-307. 被引量:2
  • 3栾洁,王文吉,陈钦元,赵培泉.维甲酸硅油防治实验性增殖性玻璃体视网膜病变[J].中华眼底病杂志,1997,13(3):174-176. 被引量:19
  • 4Tsutomu Yasukawa,Hideya Kimura,Yasuhiko Tabata,Hideki Miyamoto,Yoshihito Honda,Yuichiro Ogura. Sustained release of cis-hydroxyproline in the treatment of experimental proliferative vitreoretinopathy in rabbits[J] 2002,Graefe’s Archive for Clinical and Experimental Ophthalmology(8):672~678
  • 5R. Geoff Williams,Stanley Chang,Mark R. Comaratta,George Simoni. Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?[J] 1996,Graefe’s Archive for Clinical and Experimental Ophthalmology(8):496~503
  • 6Hesamodin Borhani,Gholam A. Peyman,Mohamad H. Rahimy,Hilary Thompson. Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU[J] 1995,International Ophthalmology(1):43~49

二级参考文献14

  • 1Weijtens O,Feron EJ,Schoemaker RC,et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctivalinjection. Am J Ophthalmol, 1999,128:192-197.
  • 2Rudnick DE,Noonan JS,Geroski DH,et al. The effect of intraocular pressure on human and rabbit scleral permeability. Invest Ophthalmol Vis Sci, 1999,40: 3054-3058.
  • 3Hainsworth DP,Pearson PA,Conklin JD,et al. Sustained release intravitreal dexamethasone. JOcul Pharmacol Ther, 1996,12: 57-63.
  • 4Chang DF,Garcia IH,Hunkele JD,et al. Phase Ⅱ results of intraocular steriod delivery system for cataract surgery. Ophthalmology, 1999,106:1172-1177.
  • 51.WadaR,HyonSH,IkadaY.Lacticacidoligomermicrospherescontaininghydrophilicdrugs.JPharmSci,1990,79∶919
  • 62.JohnsonEA,MulloyB.Simplemetachromaticassaymethodsforheparinandprotamine.JPharmPharmac,1976,28∶836
  • 73.ChandlerDB,QuansahFA,HidaT,etal.Arefinedexperimentalmodelforproliferativevitreoretinopathy.GraeferchClinExpOphthalmol,1986,224∶86
  • 84.BlumenkranzMS,ClaflinA,HajekAS.Selectionoftherapeuticagentsforintraocularproliferativedisease.ArchOphthalmol,1984,102∶598
  • 96.LippmanMM,MathewsMB.Heparin:Varyingeffectsoncellproliferationinvitroandlackofcorrelationwithanticoaculantactivity.FederationProceedings,1977,36(1)∶55
  • 107.IversonDA,DaileyWD,HartzerM,etal.Theeffectoflowmoleculerweightheparinthemitogenicityofintraocularfluidfrompattentswithproliferativeretinopathies.InvestOphthalmolVisSci,1991,32∶879

共引文献21

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部